Bourgeon Capital Management LLC Reduces Stock Holdings in Organon & Co. (NYSE:OGN)

Bourgeon Capital Management LLC trimmed its stake in Organon & Co. (NYSE:OGN - Free Report) by 77.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 67,221 shares of the company's stock after selling 233,481 shares during the period. Bourgeon Capital Management LLC's holdings in Organon & Co. were worth $969,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Alaska Department of Revenue lifted its position in shares of Organon & Co. by 417.8% in the 4th quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company's stock worth $2,267,000 after purchasing an additional 126,882 shares during the period. UBS Group AG lifted its position in Organon & Co. by 88.3% during the 3rd quarter. UBS Group AG now owns 657,912 shares of the company's stock valued at $11,421,000 after acquiring an additional 308,470 shares during the period. Nordea Investment Management AB lifted its position in Organon & Co. by 2,016.0% during the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company's stock valued at $44,648,000 after acquiring an additional 2,980,945 shares during the period. Deutsche Bank AG lifted its position in Organon & Co. by 29.7% during the 3rd quarter. Deutsche Bank AG now owns 798,210 shares of the company's stock valued at $13,857,000 after acquiring an additional 182,822 shares during the period. Finally, Thompson Siegel & Walmsley LLC lifted its position in Organon & Co. by 28.1% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,546,890 shares of the company's stock valued at $26,854,000 after acquiring an additional 339,210 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Up 1.5 %

Organon & Co. stock traded up $0.26 during mid-day trading on Monday, reaching $17.71. 2,658,875 shares of the company's stock traded hands, compared to its average volume of 2,775,709. The company has a market cap of $4.53 billion, a price-to-earnings ratio of 4.42, a PEG ratio of 0.83 and a beta of 0.82. The stock has a 50 day moving average of $17.88 and a two-hundred day moving average of $15.58. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.79.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. As a group, sell-side analysts forecast that Organon & Co. will post 4.08 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Monday, February 26th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.32%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.'s dividend payout ratio (DPR) is 28.00%.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group lifted their target price on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, February 20th.

Insider Buying and Selling at Organon & Co.

In related news, insider Kirke Weaver purchased 2,720 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.17% of the company's stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.